Welcome to Our Website Main Page...

home-imgNeuralgene is a biotechnology company with its’ flagship gene therapy, PRCN-829, an neurotropic AAV gene therapy designed to treat the neurodegenerative disorder known as Amyotrophic Lateral Sclerosis (ALS). Neuralgene has partnered with Precision StemCell of Bogota, Colombia to begin studies using image-guided administration of gene therapy to the spinal cord.

Neuralgene has several other AAV gene therapies in its’ R&D pipeline for the treatment of other neurodegenerative diseases such as Parkinson’s and Multiple Sclerosis (MS). Neuralgene plans initial testing of PRCN-829 to begin in Colombia this year. In the future, Neuralgene plans to seek approval from the FDA for trials in the USA.

Latest News & Posts

Neuralgene announces partnership with Precision StemCell of Bogota, Colombia

Neuralgene announces partnership with Precision StemCell of Bogota, Colombia to…

split

Neuralgene announces a larger study in the ALS mouse model to evaluate efficacy of PRCN-829

Neuralgene initial animal testing demonstrates safety of their gene therapy…

split

To begin testing with genetically engineered stem cell therapy

Neuralgene is partnering with Precision StemCell in Bogota, Colombia to begin testing with genetically engineered…